Company: ZLAB
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001628280-25-020478
Chunk: 55

Company: Zai Lab Ltd
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 55
---
 goals.

The Compensation Committee reviewed our performance with respect to our 2024 corporate goals and concluded that the Company had achieved most of these goals as well as significant successes beyond these goals. Based on this level of achievement, the Compensation Committee then determined that the corporate multiplier for the corporate performance element of our named executive officers’ annual incentive awards was 103%.

The discussion below outlines the Company’s 2024 corporate goals and target percentage weighting as well as our progress and achievement with respect to these goals and the related score achieved.

#### Development (Score: 33.8%; Target: 30.0%)
Goals: Execute key regulatory milestones, including new approvals and New Drug Application (“NDA”) filings, and initiate and advance key clinical trials, including with respect to enrollment, treatment, and data readouts.

Achievements: The Company achieved or exceeded the majority of its development goals for its products and product candidates, including the following:

• Regulatory Milestones: China’s National Medical Product Administration (“NMPA”) approval of the Biologics License Application (“BLA”) for VYVGART Hytrulo for the treatment of adult patients with gMG in China; NMPA approval of the NDA for XACDURO for ABC; and

<div align='center'>-40-</div>

• Initiation and Advancement of Clinical Trials: First patient treated in China in the Phase III FORTITUDE-102 study of bemarituzumab for the treatment of gastric cancer; completed enrollment in the Greater China portion of the global Phase III innovaTV 301 study of TIVDAK for recurrent or metastatic cervical cancer and the China bridging study in KarXT for the treatment of schizophrenia; and initiated global dose expansion study of ZL-1310 in SCLC.

The Company did not meet certain development goals as some related studies were deprioritized or delayed.

The Compensation Committee also considered the following additional achievements that were above and beyond the development goals approved by the Compensation Committee for 2024: completion of enrollment in China for the global Phase III FORTITUDE-102 study of bemarituzumab for gastric cancer; treatment of first patient in the Phase III study of KarXT for psychosis associated with Alzheimer’s disease; submission of an NDA for KarXT for schizophrenia; NMPA approval of the Clinical Trial Applications (“CTAs”) for efgartigimod for idiopathic inflammatory myopathies and seronegative gMG; approval of the BLA for e